PUMA BIOTECHNOLOGY financials
$9.78−0.41%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.5M | $44.8M | $75.5M | $54.5M | $52.4M | $46.0M | $59.1M | $80.5M | $47.1M | $43.8M | $72.2M | $56.1M |
| Gross profit | $44.0M | $34.4M | $52.3M | $42.3M | $40.1M | $35.5M | $45.2M | $51.4M | $36.4M | $33.0M | $47.9M | $42.8M |
| Gross margin | 77.9% | 76.7% | 69.3% | 77.7% | 76.5% | 77.1% | 76.4% | 63.9% | 77.4% | 75.5% | 66.3% | 76.3% |
| Operating income | $7.6M | -$3.8M | $17.1M | $9.6M | $6.6M | $4.0M | $13.4M | $22.1M | -$2.2M | -$2.3M | $14.8M | $8.6M |
| Net income | $8.2M | -$3.8M | $13.4M | $8.8M | $5.9M | $3.0M | $19.3M | $20.3M | -$4.5M | -$4.8M | $12.3M | $5.8M |
| Net margin | 14.5% | −8.4% | 17.8% | 16.2% | 11.2% | 6.5% | 32.7% | 25.2% | −9.6% | −11.0% | 17.0% | 10.3% |
| Diluted EPS | $0.16 | $-0.07 | $0.26 | $0.17 | $0.12 | $0.06 | $0.38 | $0.41 | $-0.09 | $-0.10 | $0.26 | $0.12 |
| EBITDA | $10.1M | -$1.2M | $19.8M | $12.3M | $9.4M | $6.8M | $16.2M | $25.0M | $729.0K | $598.0K | $14.8M | $11.5M |
| Operating cash flow | $1.6M | $15.4M | $14.4M | $9.7M | $14.1M | $3.6M | $15.6M | $11.0M | $1.0M | $11.2M | $10.5M | $10.6M |
| Free cash flow | $1.6M | $15.4M | $14.4M | $9.7M | $14.1M | $3.6M | $15.6M | $11.0M | $1.0M | $11.2M | $10.4M | $10.6M |
| Diluted shares | 52.6M | 50.8M | 51.6M | 50.9M | 50.1M | 49.9M | 50.7M | 49.2M | 48.3M | 48.2M | 48.0M | 47.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $36.5M | $36.2M | $29.6M | $53.5M | $54.7M | $63.0M |
| Short-term investments | $57.4M | $65.4M | $67.9M | $40.9M | $41.4M | $30.1M |
| Total debt | $0.00 | $11.3M | $22.5M | $33.7M | $44.9M | $56.0M |
| Total assets | $192.7M | $192.7M | $216.3M | $202.9M | $194.9M | $196.2M |
| Total liabilities | $54.2M | $64.3M | $86.0M | $87.6M | $90.2M | $99.1M |
| Shareholders' equity | $138.5M | $128.4M | $130.3M | $115.3M | $104.7M | $97.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology